{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:23:59Z","timestamp":1777983839756,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003074","name":"Ministry of Science, Technology and Productive Innovation, Argentina | Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["PIDC 2021-00006"],"award-info":[{"award-number":["PIDC 2021-00006"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003074","name":"Ministry of Science, Technology and Productive Innovation, Argentina | Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["PICT 2020-01447"],"award-info":[{"award-number":["PICT 2020-01447"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI169482"],"award-info":[{"award-number":["R01AI169482"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Janus kinase inhibitors (JAKis) are widely prescribed for autoimmune diseases, but their use is associated with increased infection risk. The mechanisms underlying this susceptibility remain unclear. CD8 T cells play a central role in antimicrobial defence, yet little is known about how JAKis reprogramme their activation and effector programmes. Here, we investigated naive and memory CD8 T cells from healthy donors stimulated in vitro in the presence of clinically relevant JAK inhibitors targeting JAK1 (JAK1i), JAK1\/2 (JAK1\/2i), or JAK1\/3 (JAK1\/3i). Flow cytometry, SCENITH, transmission electron microscopy, and RNA-seq were used to evaluate metabolic and functional programmes. We found that JAKis uncoupled phenotypic activation from metabolic reprogramming. Functionally, JAKi-treated CD8 T cells exhibited reduced activation and produced lower amounts of cytokines and cytotoxic molecules. Notably, even JAKi-treated memory CD8 T cells that upregulated CD69 and CD25 failed to engage glycolysis, showing decreased GLUT1 expression and glucose uptake. SCENITH profiling confirmed diminished glucose dependence and a shift toward mitochondrial reliance, despite reduced mitochondrial potential and structural alterations. Transcriptomic and protein analyses further revealed decreased mTOR activity and increased p53-associated transcripts, consistent with impaired growth and stress signalling. CD8 T cells from rheumatoid arthritis patients under JAKi therapy were analysed ex vivo for translational validation. These cells showed similar metabolic and signalling alterations, underscoring their clinical relevance. Altogether, these findings identify JAKis as disruptors of metabolic and signalling pathways in CD8 T cells, providing a mechanistic link between impaired effector function and the increased infection risk observed in treated patients.<\/jats:p>","DOI":"10.1038\/s41419-026-08610-7","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:53:14Z","timestamp":1774353194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disruption of metabolic licensing by JAK inhibitors constrains CD8 T cell activation and effector function"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5406-8137","authenticated-orcid":false,"given":"Luisina In\u00e9s","family":"Onofrio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Abrate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Strusberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo Guillermo","family":"Ceschin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina Luc\u00eda","family":"Montes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinthia Carolina","family":"Stempin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5871-2391","authenticated-orcid":false,"given":"Eva","family":"Acosta Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"8610_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103276","volume":"22","author":"M Benucci","year":"2023","unstructured":"Benucci M, Bernardini P, Coccia C, De Luca R, Levani J, Economou A, et al. JAK inhibitors and autoimmune rheumatic diseases. Autoimmun Rev. 2023;22:103276.","journal-title":"Autoimmun Rev"},{"key":"8610_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","volume":"398","author":"DP McLornan","year":"2021","unstructured":"McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet. 2021;398:803\u201316.","journal-title":"Lancet"},{"key":"8610_CR3","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq7074","volume":"16","author":"Q You","year":"2024","unstructured":"You Q, Chen L, Li S, Liu M, Tian M, Cheng Y, et al. Topical JAK inhibition ameliorates EGFR inhibitor-induced rash in rodents and humans. Sci Transl Med. 2024;16:eabq7074.","journal-title":"Sci Transl Med"},{"key":"8610_CR4","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1038\/s44321-024-00166-3","volume":"16","author":"K Strobl","year":"2024","unstructured":"Strobl K, Klufa J, Jin R, Artner-Gent L, Krauss D, Novoszel P, et al. JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia. EMBO Mol Med. 2024;16:3142\u201368.","journal-title":"EMBO Mol Med"},{"key":"8610_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103649","volume":"23","author":"C Ramakrishna","year":"2024","unstructured":"Ramakrishna C, Mason A, Edwards CJ. Tyrosine kinase 2 inhibitors in autoimmune diseases. Autoimmun Rev. 2024;23:103649.","journal-title":"Autoimmun Rev"},{"key":"8610_CR6","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1007\/s12325-020-01303-3","volume":"37","author":"J Pope","year":"2020","unstructured":"Pope J, Sawant R, Tundia N, Du EX, Qi CZ, Song Y, et al. Comparative efficacy of JAK inhibitors for moderate-to-severe rheumatoid arthritis: a network meta-analysis. Adv Ther. 2020;37:2356\u201372.","journal-title":"Adv Ther"},{"key":"8610_CR7","first-page":"318","volume":"34","author":"JA Hodge","year":"2016","unstructured":"Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME, et al. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34:318\u201328.","journal-title":"Clin Exp Rheumatol"},{"key":"8610_CR8","doi-asserted-by":"crossref","unstructured":"Angelini J, Talotta R, Roncato R, Fornasier G, Barbiero G, Dal Cin L, et al. JAK-Inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future. Biomolecules. 2020;10:1002.","DOI":"10.3390\/biom10071002"},{"key":"8610_CR9","doi-asserted-by":"publisher","first-page":"400","DOI":"10.23736\/S0392-0488.20.06643-2","volume":"155","author":"A Ighani","year":"2020","unstructured":"Ighani A, Georgakopoulos JR, Yeung J. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. G Ital Dermatol Venereol. 2020;155:400\u201310.","journal-title":"G Ital Dermatol Venereol"},{"key":"8610_CR10","doi-asserted-by":"crossref","unstructured":"Gialouri CG, Moustafa S, Thomas K, Hadziyannis E, Vassilopoulos D. Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies. Rheumatol Int. 2023;43:421\u201335.","DOI":"10.1007\/s00296-022-05270-6"},{"key":"8610_CR11","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1136\/annrheumdis-2021-220822","volume":"81","author":"KL Winthrop","year":"2022","unstructured":"Winthrop KL, Nash P, Yamaoka K, Mysler E, Khan N, Camp HS, et al. Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials. Ann Rheum Dis. 2022;81:206\u201313.","journal-title":"Ann Rheum Dis"},{"key":"8610_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152120","volume":"58","author":"K Winthrop","year":"2023","unstructured":"Winthrop K, Isaacs J, Calabrese L, Mittal D, Desai S, Barry J, et al. Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: a structured literature review. Semin Arthritis Rheum. 2023;58:152120.","journal-title":"Semin Arthritis Rheum"},{"key":"8610_CR13","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.3389\/fimmu.2018.02736","volume":"9","author":"F Nicoli","year":"2018","unstructured":"Nicoli F, Papagno L, Frere JJ, Cabral-Piccin MP, Clave E, Gostick E, et al. Naive CD8(+) T-cells engage a versatile metabolic program upon activation in humans and differ energetically from memory CD8(+) T-Cells. Front Immunol. 2018;9:2736.","journal-title":"Front Immunol"},{"key":"8610_CR14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41423-024-01148-8","volume":"21","author":"S Ma","year":"2024","unstructured":"Ma S, Ming Y, Wu J, Cui G. Cellular metabolism regulates the differentiation and function of T-cell subsets. Cell Mol Immunol. 2024;21:419\u201335.","journal-title":"Cell Mol Immunol"},{"key":"8610_CR15","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1146\/annurev-immunol-042617-053019","volume":"36","author":"RIK Geltink","year":"2018","unstructured":"Geltink RIK, Kyle RL, Pearce EL. Unraveling the complex interplay between T cell metabolism and function. Annu Rev Immunol. 2018;36:461\u201388.","journal-title":"Annu Rev Immunol"},{"key":"8610_CR16","doi-asserted-by":"crossref","unstructured":"Corrado M, Pearce EL. Targeting memory T cell metabolism to improve immunity. J Clin Invest. 2022;132:e148546.","DOI":"10.1172\/JCI148546"},{"key":"8610_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3389\/fcell.2018.00122","volume":"6","author":"RJ Salmond","year":"2018","unstructured":"Salmond RJ. mTOR regulation of glycolytic metabolism in T cells. Front Cell Dev Biol. 2018;6:122.","journal-title":"Front Cell Dev Biol"},{"key":"8610_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","volume":"169","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;169:361\u201371.","journal-title":"Cell"},{"key":"8610_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202048825","volume":"53","author":"AV Villarino","year":"2023","unstructured":"Villarino AV. Transcriptional programing of T cell metabolism by STAT family transcription factors. Eur J Immunol. 2023;53:e2048825.","journal-title":"Eur J Immunol"},{"key":"8610_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202250353","volume":"53","author":"VA Alamino","year":"2023","unstructured":"Alamino VA, Onofrio LI, Acosta CDV, Ferrero PV, Zacca ER, Cadile II, et al. Tofacitinib treatment of rheumatoid arthritis increases senescent T cell frequency in patients and limits T cell function in vitro. Eur J Immunol. 2023;53:e2250353.","journal-title":"Eur J Immunol"},{"key":"8610_CR21","doi-asserted-by":"crossref","unstructured":"Reddig A, Voss L, Guttek K, Roggenbuck D, Feist E, Reinhold D. Impact of different JAK inhibitors and methotrexate on lymphocyte proliferation and DNA damage. J Clin Med. 2021;10:1431.","DOI":"10.3390\/jcm10071431"},{"key":"8610_CR22","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.imbio.2019.04.003","volume":"224","author":"PC Lo","year":"2019","unstructured":"Lo PC, Maeda A, Kodama T, Takakura C, Yoneyama T, Sakai R, et al. The novel immunosuppressant prenylated quinolinecarboxylic acid-18 (PQA-18) suppresses macrophage differentiation and cytotoxicity in xenotransplantation. Immunobiology. 2019;224:575\u201384.","journal-title":"Immunobiology"},{"key":"8610_CR23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1208\/s12248-019-0378-y","volume":"21","author":"MF Mohamed","year":"2019","unstructured":"Mohamed MF, Trueman S, Othman AA, Han JH, Ju TR, Marroum P. Development of in vitro-in vivo correlation for upadacitinib extended-release tablet formulation. AAPS J. 2019;21:108.","journal-title":"AAPS J"},{"key":"8610_CR24","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/jcph.354","volume":"54","author":"JG Shi","year":"2014","unstructured":"Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1\/2 inhibitor, in healthy volunteers. J Clin Pharm. 2014;54:1354\u201361.","journal-title":"J Clin Pharm"},{"key":"8610_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2024.103541","volume":"6","author":"KE Marks","year":"2025","unstructured":"Marks KE, Adejoorin I, Sowerby J, Rao DA. Protocol for assessing T cell receptor-mediated human T cell cytotoxicity. STAR Protoc. 2025;6:103541.","journal-title":"STAR Protoc"},{"key":"8610_CR26","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.immuni.2013.10.007","volume":"39","author":"S Yao","year":"2013","unstructured":"Yao S, Buzo BF, Pham D, Jiang L, Taparowsky EJ, Kaplan MH, et al. Interferon regulatory factor 4 sustains CD8(+) T cell expansion and effector differentiation. Immunity. 2013;39:833\u201345.","journal-title":"Immunity"},{"key":"8610_CR27","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1084\/jem.20112607","volume":"209","author":"DK Finlay","year":"2012","unstructured":"Finlay DK, Rosenzweig E, Sinclair LV, Feijoo-Carnero C, Hukelmann JL, Rolf J, et al. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J Exp Med. 2012;209:2441\u201353.","journal-title":"J Exp Med"},{"key":"8610_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.mito.2017.10.006","volume":"41","author":"G Desdin-Mico","year":"2018","unstructured":"Desdin-Mico G, Soto-Heredero G, Mittelbrunn M. Mitochondrial activity in T cells. Mitochondrion. 2018;41:51\u20137.","journal-title":"Mitochondrion"},{"key":"8610_CR29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev-immunol-101819-082015","volume":"39","author":"EM Steinert","year":"2021","unstructured":"Steinert EM, Vasan K, Chandel NS. Mitochondrial metabolism regulation of T cell-mediated immunity. Annu Rev Immunol. 2021;39:395\u2013416.","journal-title":"Annu Rev Immunol"},{"key":"8610_CR30","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.devcel.2015.01.029","volume":"32","author":"AS Rambold","year":"2015","unstructured":"Rambold AS, Cohen S, Lippincott-Schwartz J. Fatty acid trafficking in starved cells: regulation by lipid droplet lipolysis, autophagy, and mitochondrial fusion dynamics. Dev Cell. 2015;32:678\u201392.","journal-title":"Dev Cell"},{"key":"8610_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.immuni.2012.10.020","volume":"38","author":"LA Sena","year":"2013","unstructured":"Sena LA, Li S, Jairaman A, Prakriya M, Ezponda T, Hildeman DA, et al. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity. 2013;38:225\u201336.","journal-title":"Immunity"},{"key":"8610_CR32","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/eji.201747443","volume":"48","author":"M Fischer","year":"2018","unstructured":"Fischer M, Bantug GR, Dimeloe S, Gubser PM, Burgener AV, Grahlert J, et al. Early effector maturation of naive human CD8(+) T cells requires mitochondrial biogenesis. Eur J Immunol. 2018;48:1632\u201343.","journal-title":"Eur J Immunol"},{"key":"8610_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.775507","volume":"9","author":"D Cui","year":"2021","unstructured":"Cui D, Qu R, Liu D, Xiong X, Liang T, Zhao Y. The cross talk between p53 and mTOR pathways in response to physiological and genotoxic stresses. Front Cell Dev Biol. 2021;9:775507.","journal-title":"Front Cell Dev Biol"},{"key":"8610_CR34","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.cmet.2020.11.007","volume":"32","author":"RJ Arguello","year":"2020","unstructured":"Arguello RJ, Combes AJ, Char R, Gigan JP, Baaziz AI, Bousiquot E, et al. SCENITH: a flow cytometry-based method to functionally profile energy metabolism with single-cell resolution. Cell Metab. 2020;32:1063\u201375.e7.","journal-title":"Cell Metab"},{"key":"8610_CR35","doi-asserted-by":"publisher","first-page":"14336","DOI":"10.1073\/pnas.1221740110","volume":"110","author":"GJ van der Windt","year":"2013","unstructured":"van der Windt GJ, O\u2019Sullivan D, Everts B, Huang SC, Buck MD, Curtis JD, et al. CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability. Proc Natl Acad Sci USA. 2013;110:14336\u201341.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8610_CR36","doi-asserted-by":"crossref","unstructured":"Raynor JL, Chi H. Nutrients: signal 4 in T cell immunity. J Exp Med. 2024;221:e20221839.","DOI":"10.1084\/jem.20221839"},{"key":"8610_CR37","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.celrep.2018.01.040","volume":"22","author":"AV Menk","year":"2018","unstructured":"Menk AV, Scharping NE, Moreci RS, Zeng X, Guy C, Salvatore S, et al. Early TCR signaling induces rapid aerobic glycolysis enabling distinct acute T cell effector functions. Cell Rep. 2018;22:1509\u201321.","journal-title":"Cell Rep"},{"key":"8610_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.63","volume":"5","author":"D Gitenay","year":"2014","unstructured":"Gitenay D, Wiel C, Lallet-Daher H, Vindrieux D, Aubert S, Payen L, et al. Glucose metabolism and hexosamine pathway regulate oncogene-induced senescence. Cell Death Dis. 2014;5:e1089.","journal-title":"Cell Death Dis"},{"key":"8610_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13067","volume":"19","author":"LA Callender","year":"2020","unstructured":"Callender LA, Carroll EC, Bober EA, Akbar AN, Solito E, Henson SM. Mitochondrial mass governs the extent of human T cell senescence. Aging Cell. 2020;19:e13067.","journal-title":"Aging Cell"},{"key":"8610_CR40","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1126\/science.aax0860","volume":"368","author":"G Desdin-Mico","year":"2020","unstructured":"Desdin-Mico G, Soto-Heredero G, Aranda JF, Oller J, Carrasco E, Gabande-Rodriguez E, et al. T cells with dysfunctional mitochondria induce multimorbidity and premature senescence. Science. 2020;368:1371\u20136.","journal-title":"Science"},{"key":"8610_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.746749","volume":"12","author":"W Zhang","year":"2021","unstructured":"Zhang W, Xu L, Zhu L, Liu Y, Yang S, Zhao M. Lipid droplets, the central hub integrating cell metabolism and the immune system. Front Physiol. 2021;12:746749.","journal-title":"Front Physiol"},{"key":"8610_CR42","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40264-025-01535-8","volume":"48","author":"R Di Napoli","year":"2025","unstructured":"Di Napoli R, Richez C, Scavone C, Singier A, Demourgues M, Mascolo A, et al. Major adverse cardiovascular events related to JAK inhibitors: a disproportionality analysis using the WHO Global Individual Case Safety Database. Drug Saf. 2025;48:943\u201352.","journal-title":"Drug Saf"},{"key":"8610_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152461","volume":"67","author":"A Goldman","year":"2024","unstructured":"Goldman A, Galper BL, Druyan A, Grossman C, Sharif K, Shechtman L, et al. Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: an analysis of postmarketing spontaneous safety reports. Semin Arthritis Rheum. 2024;67:152461.","journal-title":"Semin Arthritis Rheum"},{"key":"8610_CR44","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580\u20138.","journal-title":"Ann Rheum Dis"},{"key":"8610_CR45","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1136\/annrheumdis-2013-203756","volume":"73","author":"S Kubo","year":"2014","unstructured":"Kubo S, Yamaoka K, Kondo M, Yamagata K, Zhao J, Iwata S, et al. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis. 2014;73:2192\u20138.","journal-title":"Ann Rheum Dis"},{"key":"8610_CR46","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1007\/s13555-023-01050-7","volume":"13","author":"S Jing","year":"2023","unstructured":"Jing S, Lin Y, Dockens R, Marchisin D, He B, Girgis IG, et al. Pharmacokinetics and safety of the tyrosine kinase 2 inhibitor deucravacitinib in healthy chinese subjects. Dermatol Ther (Heidelb). 2023;13:3153\u201364.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"8610_CR47","first-page":"361","volume":"2","author":"ME Kauffman","year":"2016","unstructured":"Kauffman ME, Kauffman MK, Traore K, Zhu H, Trush MA, Jia Z, et al. MitoSOX-based flow cytometry for detecting mitochondrial ROS. React Oxyg Species (Apex). 2016;2:361\u201370.","journal-title":"React Oxyg Species (Apex)"},{"key":"8610_CR48","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34:i884\u2013i90.","journal-title":"Bioinformatics"},{"key":"8610_CR49","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1093\/nar\/gkt214","volume":"41","author":"Y Liao","year":"2013","unstructured":"Liao Y, Smyth GK, Shi W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 2013;41:e108.","journal-title":"Nucleic Acids Res"},{"key":"8610_CR50","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923\u201330.","journal-title":"Bioinformatics"},{"key":"8610_CR51","doi-asserted-by":"crossref","unstructured":"Chen Y, Chen L, Lun AT, Baldoni PL, Smyth GK. edgeR v4: powerful differential analysis of sequencing data with expanded functionality and improved support for small counts and larger datasets. Nucleic Acids Res. 2025;53:gkaf018.","DOI":"10.1093\/nar\/gkaf018"},{"key":"8610_CR52","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08610-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08610-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08610-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T20:02:31Z","timestamp":1774987351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08610-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8610"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08610-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7794494\/v1","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Ingrid Strusberg and Dr. Liliana Morales have participated as sub-investigators in clinical trials sponsored by pharmaceutical companies developing JAK inhibitors. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Instituto M\u00e9dico Strusberg (C\u00f3rdoba, Argentina). The protocol entitled \u201cEfecto de los inhibidores de JAK kinasas en la modulaci\u00f3n de la respuesta inmune de memoria en pacientes con artritis reumatoidea\u201d and its informed consent form (Protocol version 6.0, dated November 2, 2023; Consent version 5.0, dated November 2, 2023) were reviewed and approved on November 8, 2023 (Ethics Committee Reference No. 02). All participants provided written informed consent prior to inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"ChatGPT (OpenAI) was used exclusively to improve the clarity and grammar of the manuscript. The tool did not contribute to data analysis, interpretation, or scientific conclusions. All scientific content, methodology, and interpretations are the sole responsibility of the authors, and all AI-assisted edits were reviewed and approved by the authors before submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"AI-assisted language editing"}}],"article-number":"355"}}